<DOC>
	<DOCNO>NCT00849459</DOCNO>
	<brief_summary>RATIONALE : Placing gene interleukin-12 breast cancer cell may help body build immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose gene therapy treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Gene Therapy Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity maximum tolerate dose intratumoral injection adenovirus-mediated human interleukin-12 gene woman metastatic breast cancer . - Determine tumor response patient treat regimen . - Determine immune response patient treat regimen . OUTLINE : Patients receive single dose adenovirus-mediated human interleukin-12 intratumorally via percutaneous needle placement ultrasound guidance . Blood tumor tissue sample collect periodically immunological laboratory study . Samples analyze serum cytokine level ELISA ; qualitative analysis immune biomarkers IHC staining ; immune cell biomarker analysis FACS . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic adenocarcinoma breast Malignant disease skin , chest wall , site ( lymph node primary tumor breast ) accessible percutaneous needle placement injection Solitary multiple tumor Measurable disease ≥ 2 dimension physical examination CT/MRI scan Malignant tumor skin chest wall must ≥ 4 mm diameter physical examination Malignant tumor accessible site must ≥ 1 cm diameter physical examination Malignant disease organ ( addition skin chest wall metastasis ) allow Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Karnofsky performance status 70100 % Life expectancy ≥ 16 week Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 mg/dL PT normal Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 45 mL/min Serum total bilirubin ≤ 2.0 time upper limit normal ( ULN ) Serum transaminases ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Weight ≥ 30 kg ( patient treat high dose level study drug ) No active infection concurrent serious medical illness No HIV positivity No malignancy within past 5 year except follow : Inactive nonmelanoma skin cancer In situ carcinoma cervix Grade 1 papillary bladder cancer PRIOR CONCURRENT THERAPY : More 4 week since prior chemotherapy ( 6 week nitrosoureas ) No anticoagulant therapy heparin warfarin ≥ 2 month completion study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>